GEN Exclusives

More »

GEN News Highlights

More »
Mar 15, 2007

Abeille Stands to Earn $21M in Deal with SymBio

  • Abeille Pharmaceuticals and SymBio Pharmaceuticals will together develop and sell Abeille's transdermal patch for emesis, in Japan, China, Korea, Taiwan, and Singapore.

    AB-1001, is a transdermal patch for chemotherapy-induced nausea and vomiting. It is designed to deliver a commercially available 5HT3-antagonist through the skin for a continuous period of up to five days. Abeille intends to initiate a Phase III trial of AB-1001 in the second quarter of 2007.

    SymBio will pay Abeille an upfront licensing fee and milestone-based payments, which could total up to $21 million. The agreement also calls for double-digit royalty payments on commercial sales.

    Abeille also granted SymBio the right of first refusal on Abeille's next product in the field.



Jobs

GEN Jobs powered by HireLifeScience.com connects you directly to employers in pharma, biotech, and the life sciences. View 40 to 50 fresh job postings daily or search for employment opportunities including those in R&D, clinical research, QA/QC, biomanufacturing, and regulatory affairs.
 Searching...

Unable to get Jobs Listings.

More »

GEN Poll

More » Poll Results »

Lab-Grown Vaginas

Which body part do you think will be successfully engineered in the lab next?